Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alvin Farrel

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Science Advances|January 1, 2026
HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumorsDaniel Hwang, Molly C Erdman, Santosh Adhikari, et al.
The Journal of Experimental Medicine|July 14, 2025
Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastomaMarie Ménard, Hiroyuki Yoda, Nicole Nasholm, et al.
Nature Communications|December 11, 2021
Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunctionCaroline Diorio, Rawan Shraim, Laura A Vella, et al.
Communications Biology|November 18, 2022
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastomaMehran Makvandi, Minu Samanta, Paul Martorano, et al.
Nature|November 8, 2023
Targeting of intracellular oncoproteins with peptide-centric CARsMark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Nature|November 4, 2021
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARsMark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Nature|November 8, 2023
Retraction Note: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARsMark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
The New England Journal of Medicine|September 1, 2021
Treatment of Relapsing HPV Diseases by Restored Function of Natural Killer CellsAndrea Lisco, Amy P Hsu, Dimana Dimitrova, et al.
Cell Reports|August 9, 2025
NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomasPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2025
Neuronal cell adhesion molecule (NRCAM) variant defined by microexon skipping is an essential, antigenically distinct, and targetable proteoform in high-grade gliomaPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Science Advances|January 1, 2026
HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumorsDaniel Hwang, Molly C Erdman, Santosh Adhikari, et al.
The Journal of Experimental Medicine|July 14, 2025
Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastomaMarie Ménard, Hiroyuki Yoda, Nicole Nasholm, et al.
Nature Communications|December 11, 2021
Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunctionCaroline Diorio, Rawan Shraim, Laura A Vella, et al.
Communications Biology|November 18, 2022
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastomaMehran Makvandi, Minu Samanta, Paul Martorano, et al.
Nature|November 8, 2023
Targeting of intracellular oncoproteins with peptide-centric CARsMark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Nature|November 4, 2021
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARsMark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Nature|November 8, 2023
Retraction Note: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARsMark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
The New England Journal of Medicine|September 1, 2021
Treatment of Relapsing HPV Diseases by Restored Function of Natural Killer CellsAndrea Lisco, Amy P Hsu, Dimana Dimitrova, et al.
Cell Reports|August 9, 2025
NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomasPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2025
Neuronal cell adhesion molecule (NRCAM) variant defined by microexon skipping is an essential, antigenically distinct, and targetable proteoform in high-grade gliomaPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Pageof 4